200 related articles for article (PubMed ID: 22390800)
21. Editorial: aliskiren/amlodipine single-pill combinations: more evidence in favour of combination formulations for the treatment of hypertension.
Katsiki N; Athyros VG; Mikhailidis DP; Karagiannis A
Curr Vasc Pharmacol; 2012 Nov; 10(6):745-7. PubMed ID: 23113710
[TBL] [Abstract][Full Text] [Related]
22. Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.
Ram CV
Expert Rev Cardiovasc Ther; 2011 Jan; 9(1):9-19. PubMed ID: 21166525
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study.
Murray AV; Koenig W; Garcia-Puig J; Patel S; Uddin A; Zhang J
J Clin Hypertens (Greenwich); 2012 Dec; 14(12):821-7. PubMed ID: 23205748
[TBL] [Abstract][Full Text] [Related]
24. Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues.
Izzo JL; Zion AS
Ther Adv Cardiovasc Dis; 2011 Jun; 5(3):169-78. PubMed ID: 21606125
[TBL] [Abstract][Full Text] [Related]
25. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy.
Drummond W; Munger MA; Rafique Essop M; Maboudian M; Khan M; Keefe DL
J Clin Hypertens (Greenwich); 2007 Oct; 9(10):742-50. PubMed ID: 17917501
[TBL] [Abstract][Full Text] [Related]
26. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.
Oparil S; Melino M; Lee J; Fernandez V; Heyrman R
Clin Ther; 2010 Jul; 32(7):1252-69. PubMed ID: 20678674
[TBL] [Abstract][Full Text] [Related]
27. [A powerful duo: antihypertensives aliskiren and amlodipine in one tablet. Combination tablet for hypertensive patients with diabetes and overweight].
MMW Fortschr Med; 2011 May; 153(19):42-3. PubMed ID: 21612097
[No Abstract] [Full Text] [Related]
28. Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial.
Teo KK; Pfeffer M; Mancia G; O'Donnell M; Dagenais G; Diaz R; Dans A; Liu L; Bosch J; Joseph P; Copland I; Jung H; Pogue J; Yusuf S;
Eur Heart J; 2014 Jul; 35(26):1743-51. PubMed ID: 24616335
[TBL] [Abstract][Full Text] [Related]
29. Aliskiren for hypertension in adults.
Drug Ther Bull; 2008 Oct; 46(10):73-6. PubMed ID: 18832257
[TBL] [Abstract][Full Text] [Related]
30. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
31. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
[TBL] [Abstract][Full Text] [Related]
32. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial.
Schmieder RE; Philipp T; Guerediaga J; Gorostidi M; Bush C; Keefe DL
J Hypertens; 2009 Jul; 27(7):1493-501. PubMed ID: 19444142
[TBL] [Abstract][Full Text] [Related]
33. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
35. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension.
Black HR; Weinberger MH; Purkayastha D; Lee J; Sridharan K; Israel M; Hilkert R; Izzo J
J Clin Hypertens (Greenwich); 2011 Aug; 13(8):571-81. PubMed ID: 21806767
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study.
Littlejohn TW; Jones SW; Zhang J; Hsu H; Keefe DL
J Hum Hypertens; 2013 May; 27(5):321-7. PubMed ID: 23076450
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
Punzi HA
Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):12-21. PubMed ID: 24492985
[TBL] [Abstract][Full Text] [Related]
38. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A
Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536
[TBL] [Abstract][Full Text] [Related]
39. Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension.
Duggan ST; Chwieduk CM; Curran MP
Drugs; 2010 Oct; 70(15):2011-49. PubMed ID: 20883056
[TBL] [Abstract][Full Text] [Related]
40. Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.
Chrysant SG
Postgrad Med; 2011 Nov; 123(6):21-31. PubMed ID: 22104451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
